357-07-3

Basic information

• Product Name: OXYMORPHONE HCL NARCOTIC ANALGESIC
• Synonyms: OXYMORPHONE HCL NARCOTIC ANALGESIC;3,14-dihydroxy-4,5-alpha-epoxy-17-methyl-morphinan-6-onhydrochloride;4,5-alpha-epoxy-3,14-dihydroxy-17-methylmorphinan-6-onehydrochloride;morphinan-6-one,4,5-epoxy-3,14-dihydroxy-17-methyl-,hydrochloride,(5-alpha;numorphanhydrochloride;oxymorphinonehydrochloride;oxymorphone hydrochloride;(5alpha)-4,5-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one hydrochloride
• CAS NO: 357-07-3
• Molecular Formula: C₁₇H₁₉NO₄*ClH
• Molecular Weight: 338.80594
• EINECS: 206-610-5
• Mol File: 357-07-3.mol

Chemical Properties

• Boiling Point: 518.6°Cat760mmHg
• Flash Point: 267.5°C
• Appearance: /
• Density: 1.5g/cm³
• Vapor Pressure: 1.39E-11mmHg at 25°C
• Refractive Index: 1.709
• CAS DataBase Reference: OXYMORPHONE HCL NARCOTIC ANALGESIC(CAS DataBase Reference)
• NIST Chemistry Reference: OXYMORPHONE HCL NARCOTIC ANALGESIC(357-07-3)
• EPA Substance Registry System: OXYMORPHONE HCL NARCOTIC ANALGESIC(357-07-3)

Safety Data

• RIDADR: 3249
• HazardClass: 6.1(b)
• PackingGroup: III
• Hazardous Substances Data: 357-07-3(Hazardous Substances Data)

Usage

Uses

Analgesic (narcotic).

Brand name

Numorphan (Endo); Opana (Endo).

Clinical Use

Oxymorphone is a potent μ agonist (10 times greater than morphine) that is used to treat severe pain. It is used by intramuscular, subcutaneous, intravenous, and rectal routes of administration. The intramuscular dose of oxymorphone (1 mg) has a half-life of 3 to 4 hours. It is a Schedule II drug. Oxymorphone, because of its 14-hydroxy group, has low antitussive activity.

Safety Profile

Poison by ingestion, intravenous, intraperitoneal, and subcutaneous routes. An experimental teratogen. When heated to decomposition it emits toxic fumes of NOx and HCl.

InChI:InChI=1/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17?/m1/s1

Upstream product

• 124-90-3 oxycodone hydrochloride 
• 467-04-9 oripavine 
• 76-41-5 oxymorphone 

Downstream Products

• 111469-88-6 Oxymorphindole 
• 76-41-5 oxymorphone 
• 54934-75-7 6β-oxymorphol 
• 73986-27-3 C₂₄H₂₆N₂O₃ 
• 1257541-93-7 C₂₄H₂₈N₂O₃ 
• 98634-03-8 (5α,6α)-6-amino-4,5-epoxy-3,14-dihydroxy-17-methylmorphinan 

Relevant articles and documents

A method for synthesizing hydrochloric acid hydroxy morphinones

The invention discloses a synthesis method of oxymorphone hydrochloride. The synthesis method mainly comprises the following steps of: 1) alkalifying to obtain free alkali by taking oxycodone hydrochloride as an initial a raw material; 2) carrying out a demethylation reaction to obtain oxymorphone; 3) carrying out a hydrogenation reaction on the oxymorphone under acidic condition; and 4) salifying the hydrogenated product with hydrochloric acid to obtain the target product oxymorphone hydrochloride. The synthesis method disclosed by the invention has the advantages of available raw materials, high product purity and is easy to operate and is applicable to industrial production.

Processes for Making Opioids Including 14-Hydroxycodeinone and 14-hydroxymorphinone

Improved processes for making opioid products having low impurity levels including making 14-hydroxycodeinone and 14-hydroxymorphinone from thebaine and oripavine, respectively.

Forms of oxymorphone hydrochloride

The present disclosure is directed to crystalline forms of oxymorphone hydrochloride and compositions comprising any of the crystalline forms of oxymorphone hydrochloride. Also provided are processes for the preparation of crystalline forms of oxymorphone hydrochloride.

PROCESS FOR IMPROVED OPIOID SYNTHESIS

Compounds and compositions for use as starting materials or intermediate materials in the preparation of opioids including, e.g., oxymorphone base and/or an oxymorphone salt; processes for preparing these compounds and compositions; uses of these compounds and compositions in the preparation of APIs and pharmaceutical dosage forms; and uses of said APIs and pharmaceutical dosage forms in the treatment of medical conditions.

IMPROVED METHOD OF PREPARING OXYMORPHONE

The invention relates to an improved method of preparing oxymorphone or a salt thereof from oripavine. In particular, the invention relates to a method of preparing oxymorphone with a content of alpha-beta- unsaturated ketones (ABUK) 10 ppm.

CRYSTALLINE FORMS OF OXYMORPHONE HYDROCHLORIDE

The present invention is directed to crystalline forms of oxymorphone hydrochloride.

PROCESS FOR PREPARING OXYMORPHONE

Methods are provided which include converting oripavine to other opiates, including converting oripavine to 14-hydroxymorphinone and/or converting 14-hydroxymorphinone to oxymorphone. Purification and salt formation are optionally included.

METHOD FOR MAKING ANALGESICS

Improved analgesic oxymorphone hydrochloride contains less than 10 ppm of alpha, beta unsaturated ketones and pharmaceutical preparations comprising such oxymorphone hydrochloride. The oxymorphone hydrochloride is produced by reducing a starting material oxymorphone hydrochloride using gaseous hydrogen and under specified acidity, solvent system and temperature conditions. A specific polymorph of oxymorphone hydrochloride may be obtained by hydration.